Jason Rhodes

Jason Rhodes

Signal active

Partner

Bio

Jason Rhodes is a partner and focuses on the creation, development, and business strategy of novel therapeutics companies.

Jason is on the board of Replimune, Bicycle Therapeutics, and Raze Therapeutics. Prior to joining Atlas Venture in 2014, Jason was president and chief financial officer of Epizyme (NASDAQ: EPZM). Jason joined Epizyme when it was a private, research-stage company and was instrumental in charting the company’s strategic course and building the business, leading to Epizyme’s successful IPO in 2013. He established and was responsible for all business functions and led the company’s partnerships with Celgene, GSK, and Eisai, raising more than $180 million in non-equity funding while retaining U.S. product rights.

Prior to Epizyme, Jason was vice president of business development at Alnylam (NASDAQ: ALNY), where he led corporate partnerships with companies including Takeda, GSK, Isis, Cubist, Roche, Kyowa Hakko Kirin, and Medtronic as well as the spin out of Regulus Therapeutics (NASDAQ: RGLS). Together, these partnerships brought in more than $200 million in non-equity funding.

Before joining Alnylam, Jason was a founder and partner with Fidelity Biosciences, the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), and Tetraphase (NASDAQ: TTPH).

Earlier in his career, Jason worked on new business entrance, product strategy, and commercialization projects with biopharma and high tech companies.

Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.

He is a member of the Berklee College of Music Presidential Advisory Council and spends his free time running, mountain biking with his kids, and loudly watching Spanish fútbol.

Location

Boston, Massachusetts, United States, North America

Social

Primary Organization

Atlas Venture

Atlas Venture

Founded

1980

Investment

602

Lead investment

167

Exits

185

Employees

11-50

Industry

Venture Capital, Biotechnology, Health Care, Pharmaceutical

Jobs history

6

AAVantgarde Bio

Board Member

Invalid date - Current

Third Harmonic Bio

Board Member

Invalid date - Current

Raze Therapeutics

Chief Executive Officer

Invalid date - Current

K36 Therapeutics

Board of Directors

2021 - Current

Rectify Pharmaceuticals

Board Member

2021 - Current

Atlas Venture

Partner

2014 - Current

Board and Advisor Roles

0

N/A

Invest in regions

Profile Resume

Jason Rhodes is the Partner at Atlas Venture, based in United States, North America. With a background in Venture Capital, Jason Rhodes has a rich history of leadership and innovation. Jason Rhodes studied BA unknown @ Yale University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.

Recommendation from your interest

N/A

Investment portfolio

N/A

Number of investment

1

Number of exits

0

Personal investment

0

There is no personal investment available on this profile

Partner investment

17

Annouced DateOrganization NameFunding RoundInvestor NameMoney Raised
Apr 14, 2022
Be Biopharma Be Biopharma
Series B - Be Biopharma
Be Biopharma Atlas Venture
130.0M
Jun 06, 2023
AAVantgarde Bio AAVantgarde Bio
Series A - AAVantgarde Bio
AAVantgarde Bio Atlas Venture
65.3M
Jun 28, 2023
K36 Therapeutics K36 Therapeutics
Series B - K36 Therapeutics
K36 Therapeutics Atlas Venture
70.0M
Jan 23, 2024-
Series C - Accent Therapeutics
Atlas Venture
75.0M

Exits

0

There is no exit available on this Profile

Invest in industries

Recent Activity

There is no recent news or activity for this profile.